USP18 and metabolic dysfunction-associated steatotic liver disease: USP4 and USP18, as members of the USP family, have been shown to interact directly with TAK1 and subsequently de-ubiquitinate TAK1 and inhabit its activation to alleviate NAFLD [10, 12].